메뉴 건너뛰기




Volumn 68, Issue 12, 2008, Pages 1609-1619

Promising newer molecular-targeted therapies in head and neck cancer

Author keywords

Cediranib, therapeutic use; Cetuximab, therapeutic use; Erlotinib, therapeutic use; Gefitinib, therapeutic use; Head and neck cancer, treatment; Lapatinib, therapeutic use; Panitumumab, therapeutic use; Research and development; Semaxanib, therapeutic use

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; JANUS KINASE 2; LAPATINIB; MATUZUMAB; NIMOTUZUMAB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

EID: 49149087647     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868120-00001     Document Type: Review
Times cited : (11)

References (87)
  • 2
    • 33846677634 scopus 로고    scopus 로고
    • Malignancies of the head and neck: The role for molecular targeted agents
    • Agulnik M. Malignancies of the head and neck: the role for molecular targeted agents. Expert Opin Ther Targets 2007; 11: 207-17
    • (2007) Expert Opin Ther Targets , vol.11 , pp. 207-217
    • Agulnik, M.1
  • 4
    • 0035990824 scopus 로고    scopus 로고
    • End points for new agents in induction chemotherapy for locally advanced head and neck cancers
    • Monnerat C, Faivre S, Temam S, et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002; 13: 995-1006
    • (2002) Ann Oncol , vol.13 , pp. 995-1006
    • Monnerat, C.1    Faivre, S.2    Temam, S.3
  • 5
    • 14844321323 scopus 로고    scopus 로고
    • Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database
    • Carvalho AL, Nishimoto IN, Califano JA, et al. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806-16
    • (2005) Int J Cancer , vol.114 , pp. 806-816
    • Carvalho, A.L.1    Nishimoto, I.N.2    Califano, J.A.3
  • 6
    • 33748164404 scopus 로고    scopus 로고
    • Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck
    • Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2644-52
    • (2006) J Clin Oncol , vol.24 , pp. 2644-2652
    • Colevas, A.D.1
  • 7
    • 2442655601 scopus 로고    scopus 로고
    • The expanding role of systemic therapy in head and neck cancer
    • Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004; 22: 1743-52
    • (2004) J Clin Oncol , vol.22 , pp. 1743-1752
    • Cohen, E.E.1    Lingen, M.W.2    Vokes, E.E.3
  • 9
    • 34147178690 scopus 로고    scopus 로고
    • The epidermal growth factor receptor (EGFR) in head and neck cancer: Its role and treatment implications
    • Zimmermann M, Zouhair A, Azria D, et al. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 2006; 1: 11
    • (2006) Radiat Oncol , vol.1 , pp. 11
    • Zimmermann, M.1    Zouhair, A.2    Azria, D.3
  • 10
    • 35948968820 scopus 로고    scopus 로고
    • EGFR-targeting monoclonal antibodies in head and neck cancer
    • Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 2007; 7: 650-65
    • (2007) Curr Cancer Drug Targets , vol.7 , pp. 650-665
    • Astsaturov, I.1    Cohen, R.B.2    Harari, P.3
  • 11
    • 36348987149 scopus 로고    scopus 로고
    • Cetuximab: A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer
    • Blick SK, Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007; 67: 2585-607
    • (2007) Drugs , vol.67 , pp. 2585-2607
    • Blick, S.K.1    Scott, L.J.2
  • 12
    • 0028929803 scopus 로고
    • Angiogenesis in cancer, vascular, rheumatoid and other disease
    • Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31
    • (1995) Nat Med , vol.1 , pp. 27-31
    • Folkman, J.1
  • 13
    • 33745738260 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic
    • Ranieri G, Patruno R, Ruggieri E, et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-57
    • (2006) Curr Med Chem , vol.13 , pp. 1845-1857
    • Ranieri, G.1    Patruno, R.2    Ruggieri, E.3
  • 14
    • 33845874370 scopus 로고    scopus 로고
    • A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
    • Fury MG, Zahalsky A, Wong R, et al. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 2007; 25: 165-72
    • (2007) Invest New Drugs , vol.25 , pp. 165-172
    • Fury, M.G.1    Zahalsky, A.2    Wong, R.3
  • 16
    • 0037429725 scopus 로고    scopus 로고
    • The ErbB receptors and their role in cancer progression
    • Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99-110
    • (2003) Exp Cell Res , vol.284 , pp. 99-110
    • Holbro, T.1    Civenni, G.2    Hynes, N.E.3
  • 17
    • 0034788982 scopus 로고    scopus 로고
    • The ErbB receptor tyrosine family as signal integrators
    • Hynes NE, Horsch K, Olayioye MA, et al. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer 2001; 8: 151-9
    • (2001) Endocr Relat Cancer , vol.8 , pp. 151-159
    • Hynes, N.E.1    Horsch, K.2    Olayioye, M.A.3
  • 19
    • 18644386251 scopus 로고    scopus 로고
    • Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains
    • Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110: 775-87
    • (2002) Cell , vol.110 , pp. 775-787
    • Ogiso, H.1    Ishitani, R.2    Nureki, O.3
  • 20
    • 0037145061 scopus 로고    scopus 로고
    • Ligand-induced, receptor-mediated dimerization and activation of EGF receptor
    • Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002; 110: 669-72
    • (2002) Cell , vol.110 , pp. 669-672
    • Schlessinger, J.1
  • 22
    • 0141542627 scopus 로고    scopus 로고
    • Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells
    • Kruger JS, Reddy KB. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res 2003; 1: 801-9
    • (2003) Mol Cancer Res , vol.1 , pp. 801-809
    • Kruger, J.S.1    Reddy, K.B.2
  • 23
    • 0036235654 scopus 로고    scopus 로고
    • The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil
    • Masuda M, Toh S, Koike K, et al. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 2002; 93: 329-39
    • (2002) Jpn J Cancer Res , vol.93 , pp. 329-339
    • Masuda, M.1    Toh, S.2    Koike, K.3
  • 24
    • 0036632368 scopus 로고    scopus 로고
    • The phosphatidylinositol 3-Kinase AKT pathway in human cancer
    • Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501
    • (2002) Nat Rev Cancer , vol.2 , pp. 489-501
    • Vivanco, I.1    Sawyers, C.L.2
  • 25
    • 0035266290 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association
    • Ellerbroek SM, Halbleib JM, Benavidez M, et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 2001; 61: 1855-61
    • (2001) Cancer Res , vol.61 , pp. 1855-1861
    • Ellerbroek, S.M.1    Halbleib, J.M.2    Benavidez, M.3
  • 26
    • 0037329054 scopus 로고    scopus 로고
    • The role of ubiquitylation in signaling by growth factors: Implications to cancer
    • Shtiegman K, Yarden Y. The role of ubiquitylation in signaling by growth factors: implications to cancer. Semin Cancer Biol 2003; 13: 29-40
    • (2003) Semin Cancer Biol , vol.13 , pp. 29-40
    • Shtiegman, K.1    Yarden, Y.2
  • 27
    • 0036362221 scopus 로고    scopus 로고
    • Epidermal growth factor receptor dependence in human tumors: More than just expression?
    • Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002; 7 Suppl. 4: 31-9
    • (2002) Oncologist , vol.7 , Issue.SUPPL. 4 , pp. 31-39
    • Arteaga, C.L.1
  • 28
    • 33847622161 scopus 로고    scopus 로고
    • Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer
    • Cruz JJ, Ocana A, Del Barco E, et al. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007; 18: 421-30
    • (2007) Ann Oncol , vol.18 , pp. 421-430
    • Cruz, J.J.1    Ocana, A.2    Del Barco, E.3
  • 29
    • 34748831698 scopus 로고    scopus 로고
    • Biology of interactions: Antiepidermal growth factor receptor agents
    • Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007; 25: 4057-65
    • (2007) J Clin Oncol , vol.25 , pp. 4057-4065
    • Harari, P.M.1    Allen, G.W.2    Bonner, J.A.3
  • 30
    • 0021363327 scopus 로고
    • Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
    • Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44: 1002-7
    • (1984) Cancer Res , vol.44 , pp. 1002-1007
    • Masui, H.1    Kawamoto, T.2    Sato, J.D.3
  • 31
    • 0035254521 scopus 로고    scopus 로고
    • Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation
    • Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49: 427-33
    • (2001) Int J Radiat Oncol Biol Phys , vol.49 , pp. 427-433
    • Harari, P.M.1    Huang, S.M.2
  • 32
    • 0033966576 scopus 로고    scopus 로고
    • In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
    • Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701-8
    • (2000) Clin Cancer Res , vol.6 , pp. 701-708
    • Milas, L.1    Mason, K.2    Hunter, N.3
  • 33
    • 19244366949 scopus 로고    scopus 로고
    • Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
    • Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-14
    • (2000) J Clin Oncol , vol.18 , pp. 904-914
    • Baselga, J.1    Pfister, D.2    Cooper, M.R.3
  • 34
    • 32144433159 scopus 로고    scopus 로고
    • Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    • Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78
    • (2006) N Engl J Med , vol.354 , pp. 567-578
    • Bonner, J.A.1    Harari, P.M.2    Giralt, J.3
  • 35
    • 33644971314 scopus 로고    scopus 로고
    • Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm
    • Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24: 1072-8
    • (2006) J Clin Oncol , vol.24 , pp. 1072-1078
    • Pfister, D.G.1    Su, Y.B.2    Kraus, D.H.3
  • 36
    • 47349101706 scopus 로고    scopus 로고
    • Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): A phase II study [abstract]
    • Merlano MC, Numico G, Russi EG, et al. Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): a phase II study [abstract]. J Clin Oncol 2007; 25: 6043
    • (2007) J Clin Oncol , vol.25 , pp. 6043
    • Merlano, M.C.1    Numico, G.2    Russi, E.G.3
  • 37
    • 38149123171 scopus 로고    scopus 로고
    • Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303) [abstract]
    • Wanebo HJ, Ghebremichael M, Burtness B, et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303) [abstract]. J Clin Oncol 2007; 25: 6015
    • (2007) J Clin Oncol , vol.25 , pp. 6015
    • Wanebo, H.J.1    Ghebremichael, M.2    Burtness, B.3
  • 38
    • 33144461661 scopus 로고    scopus 로고
    • Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study
    • Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-54
    • (2005) J Clin Oncol , vol.23 , pp. 8646-8654
    • Burtness, B.1    Goldwasser, M.A.2    Flood, W.3
  • 39
    • 36048934209 scopus 로고    scopus 로고
    • Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy: Results of a randomized phase III (Extreme) study [abstract]
    • Vermorken J, Mesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy: results of a randomized phase III (Extreme) study [abstract]. J Clin Oncol 2007; 25: 6091
    • (2007) J Clin Oncol , vol.25 , pp. 6091
    • Vermorken, J.1    Mesia, R.2    Vega, V.3
  • 40
    • 34250180582 scopus 로고    scopus 로고
    • Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
    • Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-7
    • (2007) J Clin Oncol , vol.25 , pp. 2171-2177
    • Vermorken, J.B.1    Trigo, J.2    Hitt, R.3
  • 41
    • 23844523253 scopus 로고    scopus 로고
    • Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
    • Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-77
    • (2005) J Clin Oncol , vol.23 , pp. 5568-5577
    • Baselga, J.1    Trigo, J.M.2    Bourhis, J.3
  • 42
    • 24944490558 scopus 로고    scopus 로고
    • Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
    • Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-87
    • (2005) J Clin Oncol , vol.23 , pp. 5578-5587
    • Herbst, R.S.1    Arquette, M.2    Shin, D.M.3
  • 43
    • 34147140250 scopus 로고    scopus 로고
    • Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN) [abstract]
    • Kies MS, Garden AS, Holsinger C, et al. Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN) [abstract]. J Clin Oncol 2006; 24: 5520
    • (2006) J Clin Oncol , vol.24 , pp. 5520
    • Kies, M.S.1    Garden, A.S.2    Holsinger, C.3
  • 44
    • 0035117355 scopus 로고    scopus 로고
    • Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
    • Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23
    • (2001) Crit Rev Oncol Hematol , vol.38 , pp. 17-23
    • Yang, X.D.1    Jia, X.C.2    Corvalan, J.R.3
  • 45
    • 10744221013 scopus 로고    scopus 로고
    • Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
    • Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58: 984-90
    • (2004) Int J Radiat Oncol Biol Phys , vol.58 , pp. 984-990
    • Foon, K.A.1    Yang, X.D.2    Weiner, L.M.3
  • 46
    • 0026094165 scopus 로고
    • Humanization of a mouse monoclonal antibody by CDR-grafting: The importance of framework residues on loop conformation
    • Kettleborough CA, Saldanha J, Heath VJ, et al. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng 1991; 4: 773-83
    • (1991) Protein Eng , vol.4 , pp. 773-783
    • Kettleborough, C.A.1    Saldanha, J.2    Heath, V.J.3
  • 47
    • 17844391092 scopus 로고    scopus 로고
    • Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC) [abstract]
    • Hoffend J, Mohammed A, Eisenhut M, et al. Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC) [abstract]. J Clin Oncol 2004; 22: 3043
    • (2004) J Clin Oncol , vol.22 , pp. 3043
    • Hoffend, J.1    Mohammed, A.2    Eisenhut, M.3
  • 48
    • 2442704412 scopus 로고    scopus 로고
    • Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
    • Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22: 1646-54
    • (2004) J Clin Oncol , vol.22 , pp. 1646-1654
    • Crombet, T.1    Osorio, M.2    Cruz, T.3
  • 49
    • 49149084888 scopus 로고    scopus 로고
    • ClinicalTrials.gov. Phase II study of nimotuzumab and cisplatin/radiotherapy for locally advanced head and neck squamous cell cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00702481 [Accessed 2008 Jul 10]
    • ClinicalTrials.gov. Phase II study of nimotuzumab and cisplatin/radiotherapy for locally advanced head and neck squamous cell cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00702481 [Accessed 2008 Jul 10]
  • 50
    • 1842772526 scopus 로고    scopus 로고
    • Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
    • Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85
    • (2004) J Clin Oncol , vol.22 , pp. 77-85
    • Soulieres, D.1    Senzer, N.N.2    Vokes, E.E.3
  • 51
    • 0032695910 scopus 로고    scopus 로고
    • Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
    • Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739-48
    • (1999) J Pharmacol Exp Ther , vol.291 , pp. 739-748
    • Pollack, V.A.1    Savage, D.M.2    Baker, D.A.3
  • 52
    • 34250208469 scopus 로고    scopus 로고
    • Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study
    • Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007; 25: 2178-83
    • (2007) J Clin Oncol , vol.25 , pp. 2178-2183
    • Siu, L.L.1    Soulieres, D.2    Chen, E.X.3
  • 53
    • 34250195788 scopus 로고    scopus 로고
    • Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib
    • Agulnik M, da Cunha Santos G, Hedley D, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007; 25: 2184-90
    • (2007) J Clin Oncol , vol.25 , pp. 2184-2190
    • Agulnik, M.1    da Cunha Santos, G.2    Hedley, D.3
  • 54
    • 41949113428 scopus 로고    scopus 로고
    • Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [abstract]
    • Kim ES, Kies MS, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [abstract]. J Clin Onc 2007; 25: 6013
    • (2007) J Clin Onc , vol.25 , pp. 6013
    • Kim, E.S.1    Kies, M.S.2    Glisson, B.S.3
  • 55
    • 20144376211 scopus 로고    scopus 로고
    • A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group
    • Goss G, Hirte H, Miller Jr WH, et al. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 2005; 23: 147-55
    • (2005) Invest New Drugs , vol.23 , pp. 147-155
    • Goss, G.1    Hirte, H.2    Miller Jr, W.H.3
  • 56
    • 3242658931 scopus 로고    scopus 로고
    • Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacy
    • Wolf M, Swaisland H, Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 2004; 10: 4607-13
    • (2004) Clin Cancer Res , vol.10 , pp. 4607-4613
    • Wolf, M.1    Swaisland, H.2    Averbuch, S.3
  • 57
    • 36849051467 scopus 로고    scopus 로고
    • Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer
    • Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007; 25: 4880-6
    • (2007) J Clin Oncol , vol.25 , pp. 4880-4886
    • Chen, C.1    Kane, M.2    Song, J.3
  • 58
    • 0037674062 scopus 로고    scopus 로고
    • Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
    • Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-7
    • (2003) J Clin Oncol , vol.21 , pp. 1980-1987
    • Cohen, E.E.1    Rosen, F.2    Stadler, W.M.3
  • 59
    • 28544432807 scopus 로고    scopus 로고
    • Phase II trial of gefitinib 250mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    • Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 8418-24
    • (2005) Clin Cancer Res , vol.11 , pp. 8418-8424
    • Cohen, E.E.1    Kane, M.A.2    List, M.A.3
  • 60
    • 29144471675 scopus 로고    scopus 로고
    • Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [abstract]
    • Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [abstract]. J Clin Oncol 2005; 23: 5531
    • (2005) J Clin Oncol , vol.23 , pp. 5531
    • Wheeler, R.H.1    Jones, D.2    Sharma, P.3
  • 61
    • 31344471197 scopus 로고    scopus 로고
    • Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck [abstract]
    • Belón J, Irigoyen A, Rodríguez I, et al. Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck [abstract]. J Clin Oncol 2005; 23: 5563
    • (2005) J Clin Oncol , vol.23 , pp. 5563
    • Belón, J.1    Irigoyen, A.2    Rodríguez, I.3
  • 62
    • 34548533134 scopus 로고    scopus 로고
    • Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands
    • Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007; 25: 3978-84
    • (2007) J Clin Oncol , vol.25 , pp. 3978-3984
    • Agulnik, M.1    Cohen, E.W.2    Cohen, R.B.3
  • 63
    • 33748636081 scopus 로고    scopus 로고
    • A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) [abstract]
    • Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2006; 24: 5568
    • (2006) J Clin Oncol , vol.24 , pp. 5568
    • Abidoye, O.O.1    Cohen, E.E.2    Wong, S.J.3
  • 64
    • 34147155082 scopus 로고    scopus 로고
    • A phase I, open label study ( EGF 100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]
    • Bourhis J, Harrington K, Rosine D, et al. A phase I, open label study ( EGF 100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. Ann Oncol 2006; 17 (9s): 180
    • (2006) Ann Oncol , vol.17 , Issue.9 S , pp. 180
    • Bourhis, J.1    Harrington, K.2    Rosine, D.3
  • 65
    • 49149113323 scopus 로고    scopus 로고
    • ClinicalTrials.gov. Lapatinib versus placebo given concurrently with cisplatin and radiotherapy in patients with head and neck cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00387127 [Accessed 2008 Jul 10]
    • ClinicalTrials.gov. Lapatinib versus placebo given concurrently with cisplatin and radiotherapy in patients with head and neck cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00387127 [Accessed 2008 Jul 10]
  • 66
    • 25144496041 scopus 로고    scopus 로고
    • The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function
    • Bahr C, Groner B. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 2005; 23: 1-14
    • (2005) Growth Factors , vol.23 , pp. 1-14
    • Bahr, C.1    Groner, B.2
  • 67
    • 0033906634 scopus 로고    scopus 로고
    • Structure and function of the type 1 insulin-like growth factor receptor
    • Adams TE, Epa VC, Garrett TP, et al. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57: 1050-93
    • (2000) Cell Mol Life Sci , vol.57 , pp. 1050-1093
    • Adams, T.E.1    Epa, V.C.2    Garrett, T.P.3
  • 68
    • 34547107855 scopus 로고    scopus 로고
    • Insulin-like growth factor receptor as a therapeutic target in head and neck cancer
    • Barnes CJ, Ohshiro K, Rayala SK, et al. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007; 13: 4291-9
    • (2007) Clin Cancer Res , vol.13 , pp. 4291-4299
    • Barnes, C.J.1    Ohshiro, K.2    Rayala, S.K.3
  • 70
    • 21244493635 scopus 로고    scopus 로고
    • Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling
    • Mitsiades CS, Mitsiades N. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther 2005; 5: 487-99
    • (2005) Expert Rev Anticancer Ther , vol.5 , pp. 487-499
    • Mitsiades, C.S.1    Mitsiades, N.2
  • 71
    • 34249748693 scopus 로고    scopus 로고
    • Role of insulin-like growth factor 1 receptor signalling in cancer
    • Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 2007; 96 Suppl.: R2-6
    • (2007) Br J Cancer , vol.96 , Issue.SUPPL.
    • Larsson, O.1    Girnita, A.2    Girnita, L.3
  • 72
    • 49149094194 scopus 로고    scopus 로고
    • ClinicalTrials.gov. Phase 1 study of BIIB022 (anti-IGF-1R monoclonal antibody) in relapsed/refractory solid tumors [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00555724 [Accessed 2008 Jul 10]
    • ClinicalTrials.gov. Phase 1 study of BIIB022 (anti-IGF-1R monoclonal antibody) in relapsed/refractory solid tumors [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00555724 [Accessed 2008 Jul 10]
  • 73
    • 0025141337 scopus 로고
    • What is the evidence that tumors are angiogenesis dependent?
    • Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6
    • (1990) J Natl Cancer Inst , vol.82 , pp. 4-6
    • Folkman, J.1
  • 74
    • 34548850080 scopus 로고    scopus 로고
    • Molecular design and clinical development of VEGFR kinase inhibitors
    • Zhong H, Bowen JP. Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 2007; 7: 1379-93
    • (2007) Curr Top Med Chem , vol.7 , pp. 1379-1393
    • Zhong, H.1    Bowen, J.P.2
  • 75
    • 0029006696 scopus 로고
    • Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
    • Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-6
    • (1995) Nature , vol.376 , pp. 62-66
    • Shalaby, F.1    Rossant, J.2    Yamaguchi, T.P.3
  • 76
    • 14644411058 scopus 로고    scopus 로고
    • Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: A meta-analysis
    • Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005; 11: 1434-40
    • (2005) Clin Cancer Res , vol.11 , pp. 1434-1440
    • Kyzas, P.A.1    Cunha, I.W.2    Ioannidis, J.P.3
  • 77
    • 16444373306 scopus 로고    scopus 로고
    • Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2
    • Kyzas PA, Stefanou D, Batistatou A, et al. Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol 2005; 18: 485-94
    • (2005) Mod Pathol , vol.18 , pp. 485-494
    • Kyzas, P.A.1    Stefanou, D.2    Batistatou, A.3
  • 78
    • 44649195401 scopus 로고    scopus 로고
    • Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC) [abstract]
    • Choong NW, Haraf DJ, Cohen EE, et al. Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC) [abstract]. J Clin Oncol 2007; 25: 6043
    • (2007) J Clin Oncol , vol.25 , pp. 6043
    • Choong, N.W.1    Haraf, D.J.2    Cohen, E.E.3
  • 79
    • 36048982710 scopus 로고    scopus 로고
    • Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN) [abstract]
    • Savvides P, Greskovich J, Bokar J, et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN) [abstract]. J Clin Oncol 2007; 25: 6068
    • (2007) J Clin Oncol , vol.25 , pp. 6068
    • Savvides, P.1    Greskovich, J.2    Bokar, J.3
  • 80
    • 36049031069 scopus 로고    scopus 로고
    • Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): An interim analysis [abstract]
    • Karamouzis MV, Friedland D, Johnson R, et al. Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): an interim analysis [abstract]. J Clin Oncol 2007; 25: 6049
    • (2007) J Clin Oncol , vol.25 , pp. 6049
    • Karamouzis, M.V.1    Friedland, D.2    Johnson, R.3
  • 81
    • 51349157966 scopus 로고    scopus 로고
    • pKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC) [abstract]
    • Seiwert TY, Davis DW, Yan D, et al. pKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC) [abstract]. J Clin Oncol 2007; 25: 6021
    • (2007) J Clin Oncol , vol.25 , pp. 6021
    • Seiwert, T.Y.1    Davis, D.W.2    Yan, D.3
  • 82
    • 36048978575 scopus 로고    scopus 로고
    • A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial [abstract]
    • Williamson SK, Moon J, Huang CH, et al. A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): a Southwest Oncology Group (SWOG) trial [abstract]. J Clin Oncol 2007; 25: 6044
    • (2007) J Clin Oncol , vol.25 , pp. 6044
    • Williamson, S.K.1    Moon, J.2    Huang, C.H.3
  • 83
    • 34548504810 scopus 로고    scopus 로고
    • Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
    • Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-73
    • (2007) J Clin Oncol , vol.25 , pp. 3766-3773
    • Elser, C.1    Siu, L.L.2    Winquist, E.3
  • 84
    • 34347333556 scopus 로고    scopus 로고
    • Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: Antitumour supra-additive effects on human head and neck cancer xenografts
    • Bozec A, Formento P, Lassalle S, et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 2007; 97: 65-72
    • (2007) Br J Cancer , vol.97 , pp. 65-72
    • Bozec, A.1    Formento, P.2    Lassalle, S.3
  • 85
    • 49149119386 scopus 로고    scopus 로고
    • ClinicalTrials.gov. The effects of AZD2171 & gefitinib in patients with non-small cell lung cancer or head & neck cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00243347 [Accessed 2008 Jul 10]
    • ClinicalTrials.gov. The effects of AZD2171 & gefitinib in patients with non-small cell lung cancer or head & neck cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00243347 [Accessed 2008 Jul 10]
  • 86
    • 33845789166 scopus 로고    scopus 로고
    • Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer
    • Bianco C, Giovannetti E, Ciardiello F, et al. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 2006; 12: 7099-107
    • (2006) Clin Cancer Res , vol.12 , pp. 7099-7107
    • Bianco, C.1    Giovannetti, E.2    Ciardiello, F.3
  • 87
    • 33947732141 scopus 로고    scopus 로고
    • Antitumor effects of ZD6474 on head and neck squamous cell carcinoma
    • Sano D, Kawakami M, Fujita K, et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 2007; 17: 289-95
    • (2007) Oncol Rep , vol.17 , pp. 289-295
    • Sano, D.1    Kawakami, M.2    Fujita, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.